1. Home
  2. ISOU vs CBIO Comparison

ISOU vs CBIO Comparison

Compare ISOU & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ISOU

IsoEnergy Ltd.

HOLD

Current Price

$10.72

Market Cap

680.3M

Sector

N/A

ML Signal

HOLD

CBIO

Crescent Biopharma Inc.

HOLD

Current Price

$20.70

Market Cap

557.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ISOU
CBIO
Founded
2016
2003
Country
Canada
United States
Employees
24
44
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
680.3M
557.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ISOU
CBIO
Price
$10.72
$20.70
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$26.67
AVG Volume (30 Days)
84.7K
267.4K
Earning Date
05-26-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$279.20
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.94
$8.72
52 Week High
$13.58
$27.41

Technical Indicators

Market Signals
Indicator
ISOU
CBIO
Relative Strength Index (RSI) 43.97 55.11
Support Level $9.62 $10.83
Resistance Level $11.90 $21.14
Average True Range (ATR) 0.78 1.96
MACD -0.21 -0.07
Stochastic Oscillator 17.12 81.07

Price Performance

Historical Comparison
ISOU
CBIO

About ISOU IsoEnergy Ltd.

IsoEnergy Ltd is engaged in the acquisition, exploration, and evaluation of uranium properties in Canada. The company's project profile includes Geiger, Thorburn Lake, Full Moon, Edge, Collins Bay Extension, North Thorburn, 2Z Lake, and Madison. It operates in Canada, the United States, and Australia.

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: